Aptamers 2014

See you at Aptamers 2015
31 March – 01 April 2015
St Hilda’s College, Oxford, UK
Contact us on: AptamersOxford@gmail.com

Aptamers are a new class of molecules with a great potential to rival monoclonal antibodies in therapeutic, diagnostic, analytical as well as basic research applications. Described just over two decades ago, there has been an ever growing interest in these molecules as evidenced by the considerable increase in the number of related publications. Furthermore, the field of aptamer technology received a great boost in 2004 after the first FDA approved drug, Macugen, to treat age related macular degeneration, and later the development of the first aptamer based diagnostic platform for the analysis of mycotoxins in grain. In subsequent years there has been an outstanding growth in the Aptamer based companies and the range of developed products. IsmailAptamers 2014 was our first international meetings at Oxford that brought together the aptamer community from both academia and industry and solution providers. The meeting was chaired by Professor Said Ismail (University of Jordan, Amman, Jordan) and also witnessed the launch of The International Society on Aptamers, which will provide a dedicated platform and a focal point to aptamer researchers and industrial partners for interaction and collaboration. Based on the excellent success of Aptamers 2014, we are pleased to announce our second annual symposium on Aptamers, Aptamers 2015, which will be held at St Hilda’s College on 31 March – 01 April 2015. The symposium will be co-hosted with our first symposium on antisense and catalytic nucleic acids, Oligomer 2015.

  • Day-1: 24th March 2014

    St Edmund's Hall, The Jarvis Doctorow Hall
    SESSION 1: Therapeutic Applications

    Aptamers: A world of structural and functional diversity (Keynote Address)
    Jean-Jacques Toulmé,
    University of Bordeaux, France

    The integration of chiral principles into the SELEX process – Development of Spiegelmer therapeutics
    Axel Vater,
    NOXXON Pharma AG, Germany

    Multi-functional aptamer-miRNA conjugates for targeted cancer therapy
    Vittorio de Franciscis
    , Istituto per l’Endocrinologia e l’Oncologia Sperimentale del CNR “G. Salvatore”, Italy

    Aptamers: Promising Molecules for Cancer Stem Cell Targeting
    Said Ismail,
    University of Jordan, Jordan

    Aptamers as effective cancer stem cell targeting modalities
    Sarah Shigdar
    , Deakin University, Australia

    Using aptamers to unmask the multi-tasking roles of viral RNAs
    Peter Stockley
    , Leeds University, UK

    Use of stem cell specific aptamers for in vivo tissue engineering
    Meltem Avci-Adali,
    University Hospital Tuebingen, Germany

    SESSION 2: Diagnostic and Analytical Applications

    Aptamers coming of age and their application in biomarker discovery (Keynote Address)
    David Bunka, Aptamer Group, UK

    Aptamers and analytical sciences for the development of challenging diagnostics
    Anne Varenne
    , Université Paris Descartes, France

    High affinity truncated aptamer against the anaphylatic toxin ß-conglutin (Lup-an-1)
    Ciara O'Sullivan,
    Universitat Rovira i Virgili, Spain

    Identification of tumor targeting aptamers from cell-SELEX to in vivo molecular imaging
    Frédéric Ducongé
    , Université Paris Sud, France

    Aptamers in affinity separeation
    Johanna-Gabriela Walter
    , Gottfried-Wilhelm-Leibniz Universität, Germany

    Aptamers for environmental applications
    Beate Strehlitz
    , Helmholtz Centre for Environmental Research, Germany

    Stabilized Interleukin-6 receptor binding RNA aptamers
    Katharina Berg
    , University of Hamburg, Germany

    Aptamer biosensor for small molecules detection using Surface Plasmon Resonance imaging
    Feriel Melaine
    , CEA-CNRS-UJF-Grenoble, France

    Porous silicon-based aptasensors
    Katharina Urmann,
    Technion Haifa, Israel

    SOMAmers inhibit IL-6 signaling by blocking its interaction with IL-6 Rα and gp130 receptors
    Shashi Gupta,
    SomaLogic, USA

     

    Day-2: 25th March 2014

    St Hilda's College, the Jacqueline du Pré Music Building (JdP)

    Welcome coffee and poster viewing in the JdP Foyer

    SESSION 3: New Trends in Aptamer Technology

    Use of hybridization “stick” methods to attach aptamer and cargo: design considerations
    Dr Mark Behlke
    , Integrated DNA Technologies, USA

    Bringing light into the black box of SELEX experiments
    Michael Blank,
    CSO, AptaIT, Germany

    Fast and quantitative analysis of aptamer-target interactions using microscale thermophoresis
    Thomas Schuber
    , CEO, 2bind GmbH, Regensburg, Germany

    Aptamer modules and assemblies for exogenous control of biomolecule function
    Günter Mayer,
    University of Bonn, Germany

    Mechanistic insights into engineered riboswitches
    Beatrix Suess, Frankfurt University, Germany

    Monitoring aptamer-protein interactions using tunable resistive pulse sensing
    Mark Platt
    , Loughborough University (UK)

    In vitro selection of RNA aptamers against photoswitchable molecules
    Martin Michael Rudolph, Technical University Darmstadt, Germany

    Aptamer selection for specific recognition of non-human sialic acid: n-glycolyl neuraminic acid (Neu5Gc)
    Shashank Sharma, University of Ireland Galway, Ireland

  • (Presenter in bold)

    ---------------------------------------------------------------------------------------------------------------

    Functionalizing liposomes with anti-CD44 Aptamer for specific targeted drug delivery into cancer cells

    Walhan Alshaer1, Hervé HILLAIREAU1, Juliette VERGNAUD1, Nidaa ABABNEH2, Said ISMAIL2, Elias FATTAL1

    1 UMR CNRS 8612, Institut Galien Paris-Sud, Faculté Pharmacie, Université Paris-Sud, 5, rue J-B Clément, 92290 Châtenay-Malabry, France.
    2Molecular Biology Research Laboratory, Faculty of Medicine, University of Jordan, Amman 11942, Jordan

    ---------------------------------------------------------------------------------------------------------------

    Selective targeting of Aptamer for delivery, therapeutic and imagining in cancer disease

    Paola Amero, Carla Lucia Esposito, Silvia Catuogno, Gennaro De Vita, Simona Camorani, Anna Rienzo, Raffaela Fontanella, Laura Cerchia, Vittorio de Franciscis

    Istituto per l’Endocrinologia e l’Oncologia Sperimentale del CNR ‘‘G. Salvatore’’, Naples, Italy

    ---------------------------------------------------------------------------------------------------------------

    Aptamers in the study of Fibroblast Growth Factor 8b

    Robert S. Bedenbaugh, Gwendolyn M. Stovall, Andrew D. Ellington

    Institute for Cellular and Molecular Biology, The University of Texas at Austin, 103 W. 24th Street PAI 3.04N, Austin TX, 78712, USA

    ---------------------------------------------------------------------------------------------------------------

    Stabilized Interleukin-6 receptor binding RNA aptamers

    Katharina Berg, Cindy Meyer, Inken Lorenzen, Joachim Grötzinger, Stefan Rose-John and Ulrich Hahn

    University of Hamburg, Department Chemistry, Institute for Biochemistry and Molecular Biology, Martin-Luther-King-Platz 6, 20146 Hamburg, Germany

    ---------------------------------------------------------------------------------------------------------------

    A sensitive resistive pulse sensing assay for monitoring aptamer-ligand interactions

    Emily Rose Billinge and Mark Platt

    Department of Chemistry, Centre for Analytical Science, Loughborough University, Loughborough, LE11 3TU, United Kingdom

    ---------------------------------------------------------------------------------------------------------------

    The development of aptamers and their applications in health sciences

    Emma Blundell1, Andy Jackson2*, Jingfeng Huang2,3, Alfred Tok3, Myra A.Nimmo2 and Mark Platt1

    1 Department of Chemistry, Loughborough University, Loughborough, LE11 3TU, UK
    2 Leicester-Loughborough Diet, Lifestyle & Physical Activity Biomedical Research Unit, School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, LE11 3TU, UK
    3 Institute for Sports Research, Materials Science and Engineering, Nanyang Technological University, 50 Nanyang Avenue, Singapore

    ---------------------------------------------------------------------------------------------------------------

    Apta-PCR assay for the detection of Burkitt’s lymphoma related cells via a caged aptamer

    Laia Civit1, Alessandro Pinto2, Ciara K. O’Sullivan3, Günter Mayer1

    1 Life and Medical Sciences Institute, University of Bonn, Gerhard-Domagk Str. 1, Bonn, Germany
    2 NanoBioSeparations Group, POLYMAT, University of the Basque Country UPV/EHU, Avda. Tolosa 72, San Sebastian, Spain
    3 Nanotechnology and Bioanalysis Group, Chemical Engineering Department, Universitat Rovira i Virgili, Av. Països Catalans 26, Tarragona, Spain

    ---------------------------------------------------------------------------------------------------------------

    2’-Modified RNA aptamers against insulin-like growth factor I receptor

    Anna Davydova1, Maria Vorobjeva1, Jean-Christophe Francois2 and Alya Venyaminova1

    1Institute of Chemical Biology and Fundamental Medicine SB RAS, Lavrentieva ave. 8, Novosibirsk, 630090, Russia
    2Centre de Recherche Saint-Antoine INSERM - UPMC, UMR S 938, 27 rue Chaligny F-75571 PARIS 12

    ---------------------------------------------------------------------------------------------------------------

    Fluorescence Polarization detection of D-AMP and derivatives using a new Aptamer-PNA Probe

    Emma Goux, Valérie Guieu, Corinne Ravelet, Eric Peyrin

    University of Grenoble, Département de pharmacochimie moléculaire 470, rue de la Chimie 38400 St Martin d'Heres

    ---------------------------------------------------------------------------------------------------------------

    Aptamer controlled splicing in mammalian cells

    Florian Groher, Janina Langner, Beatrix Suess

    TU Darmstadt, FB Biologie, Schnittspahnstraße 10, 64287 Darmstadt, Germany

    ---------------------------------------------------------------------------------------------------------------

    Aptamers Targeting the Mannose Receptor

    Silvana Hassel1, Verena Schütte2, Sven Burgdorf2, and Günter Mayer1

    1Life and Medical Sciences (LIMES), University of Bonn, Gerhard-Domagk-Str. 1, Germany
    2Life and Medical Sciences (LIMES), University of Bonn, Carl-Troll-Str. 31, Germany

    ---------------------------------------------------------------------------------------------------------------

    Post-SELEX modification of a Streptavidin-Binding Aptamer by LNA- and α-L-LNA-substitutions

    Anna S. Jørgensen1, Lykke H. Hansen2, Birte Vester2, Jesper Wengel1*

    1 Nucleic Acid Center, Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55, 5230 Odense M, Denmark
    2 Nucleic Acid Center, Department of Biochemistry and Molecular Biology, University of Southern Denmark, Campusvej 55, 5230 Odense M, Denmark

    ---------------------------------------------------------------------------------------------------------------

    Aptamer-based control of intraneuronal signal transduction

    Sabine Lennarz1, Therese Christine Alich2, Heinz Beck2,3, and Günter Mayer1,

    1 Life and Medical Sciences (LIMES) Institute, Prog. Unit Chemical Biology and Medicinal Chemistry, University of Bonn, Gerhard-Domagk-Str.1, 53121 Bonn, Germany
    2Laboratory of Experimental Epileptology and Cognition Research, Department of Epileptology, Sigmund-Freud Str. 25, 53105 Bonn, Germany
    3Deutsches Zentrum für Neurodegenerative Erkrankungen in der Helmholtz Gemeinschaft, Ludwig-Erhard-Allee 2, 53175 Bonn, Germany

    ---------------------------------------------------------------------------------------------------------------

    Development of aptasensors for biomedical and agri-food applications based on Surface Plasmon Resonance imaging

    Elodie Ly-Morin1, Karen Mercier1, Stephen Vance², Marinella Sandros², Gergely Lautner3, Róbert E. Gyurcsányi3 and Chiraz Frydman1

    1HORIBA Scientific, Palaiseau, France
    2 University of North Carolina, Greesboro, USA
    3 Budapest University of Technology and Economics, Budapest, Hungary

    ---------------------------------------------------------------------------------------------------------------

    Novel T7 RNA polymerases for the incorporation of modified nucleotides during aptamer selection

    Hannah G. McDonald 1Ÿ, Adam MeyerŸ 1, Bradley Hall 2, Andrew D. Ellington

    1 Institute for Cellular and Molecular Biology, The University of Texas at Austin
    2 Altermune Technologies, 1 University Station, Austin, TX 78712

    ---------------------------------------------------------------------------------------------------------------

    In vitro selection of RNA aptamers for the interleukin-6 receptor

    Florian Mittelberger1, Cindy Meyer2, Georg Waetzig3, Ulrich Hahn1

    1Department of Chemitry, Institute of Biochemistry and Molecular Biology, University of Hamburg, Martin-Luther-King-Platz 6, 20146 Hamburg
    2Howard Hughes Medical Institute, Laboratory of RNA Molecular Biology, Rockefeller University, 1230 York Avenue, Box 186, New York, NY 10065
    3CONARIS Research Institute AG, Schauenburgerstr. 116, 24118 Kiel

    ---------------------------------------------------------------------------------------------------------------

    The identification of novel aptamers to glioma

    Karl Norris, Lisa Shaw, Jane Elizabeth Alder, Clare Louise Lawrence

    University of Central Lancashire, Fylde road, Preston, Lancashire, PR1 2HE, UK

    ---------------------------------------------------------------------------------------------------------------

    Using microarrays for the evolution of new aptamer sequences, and the exploration of sequence activity relationships

    Mark Platt

    Department of Chemistry, Centre for Analytical Science, Loughborough University, Loughborough, LE11 3TU, United Kingdom

    ---------------------------------------------------------------------------------------------------------------

    Target responsive electrochemical aptasensors

    Sanaz Pilehvar and Karolien De Wael

    AXES research group, Department of Chemistry, University of Antwerp, Gronenborgerlaan 171, 2020 Antwerp, Belgium

    ---------------------------------------------------------------------------------------------------------------

    An enhanced aptamer sequence as tool for targeted drug delivery: rational engineering of a DNA aptamer against transferrin receptor

    David Porciani1,2, Giovanni Signore2*, Riccardo Nifosì1, Laura Marchetti1, Paolo Mereghetti2 and Fabio Beltram1

    1NEST, Scuola Normale Superiore and Istituto Nanoscienze-CNR, Piazza San Silvestro 12 Pisa, 56127, Italy
    2Center for Nanotechnology Innovation@NEST, Istituto Italiano di Tecnologia, Piazza San Silvestro 12 Pisa, 56127, Italy

    ---------------------------------------------------------------------------------------------------------------

    Agonistic CD200R1 DNA Aptamers are Potent Immunosuppressants both In Vitro and In Vivo and Prolong Allogeneic Skin Graft Survival

    Aaron Prodeus ab, Marzena Cydzik ab, Reginald Gorczynski d, Eric Huang b, and Jean Gariepy abc

    a Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada M5S3M2,
    b Physical Sciences, Sunnybrook Research Institute, Toronto, ON, Canada M4N3M5
    c Department of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada M5S3M2
    d Departments of Surgery and Immunology, University Health Network and The Toronto General Hospital, Toronto, ON, Canada M5G1L7

    ---------------------------------------------------------------------------------------------------------------

    In vitro selection of RNA aptamers against photoswitchable molecules

    Martin Michael Rudolph1, Thomas Halbritter2, Alexander Heckel2,Beatrix Suess1

    1Department of Biology, Technical University Darmstadt, Schnittspahnstr. 10, 64287 Darmstadt, Germany
    2 Department of Organic Chemistry and Chemical Biology, Goethe University Frankfurt, Max-von-Laue Str. 7, 60438 Frankfurt am Main, Germany

    ---------------------------------------------------------------------------------------------------------------

    Aptamer selection for specific recognition of non-human sialic acid: n-glycolyl neuraminic acid (Neu5Gc)

    Shashank Sharma, Hsien-Yu Tsai, Satbir Kaur Gill, Marian Kane, Lokesh Joshi

    Glycoscience Group, National Centre for Biomedical Engineering and Science (NCBES), National University of Ireland Galway, Ireland

    ---------------------------------------------------------------------------------------------------------------

    A new DNA aptamer for protein A and its characterization by SPR-based interaction analysis

    Regina Stoltenburg and Beate Strehlitz

    Helmholtz Centre for Environmental Research – UFZ, Permoserstraße 15, 04318 Leipzig, Germany

    ---------------------------------------------------------------------------------------------------------------

    Click-SELEX: A versatile method for the selection of chemically functionalized aptamers

    Fabian Tolle1, Julian Victor1, Felix Friedrich2, Alexander Heckel2, Günter Mayer1

    1LIMES Institute, University of Bonn, Gerhard-Domagk-Str. 1, 53121 Bonn, Germany
    2 Goethe University Frankfurt a. M, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany

    ---------------------------------------------------------------------------------------------------------------

    Modified nucleotides in aptamers: de novo selection and post modification strategies

    Christina Udesen

    Wengel Group at Nucleic Acid Center, Dept. of Physics, Chemistry and Pharmacology, Southern University of Denmark, Campusvej 55, DK-5230, Denmark

    ---------------------------------------------------------------------------------------------------------------

    2'-Modified RNA aptamer against autoantibodies associated with multiple sclerosis and bioluminescent probe on its basis

    Maria A Vorobjeva1, Vasilisa V Krasitskaya2, Valentina V Timoshenko1, Georgy A Nevinsky1, Ludmila A Frank2 and Alya G Venyaminova1

    1 Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Novosibirsk 630090, Russia
    2 Institute of Biophysics, Siberian Branch, Russian Academy of Sciences, Krasnoyarsk 660036, Russia

    ---------------------------------------------------------------------------------------------------------------

    Comparison Between SELEX and Single-Step Selection

    Robert Wilson and Andrew Cossins

    Liverpool University, Institute of Integrative Biology, Liverpool, UK

    ---------------------------------------------------------------------------------------------------------------

    Aptamer-based early lung cancer diagnosis via CTC detection

    G. S. Zamay1, O. S. Kolovskaya1, A. S. Zamay1 O. A. Zubkova1, E. A. Spivak1, Y. E. Glazyrin1, M. V. Berezovsky2, T. N. Zamay1

    1Krasnoyarsk Voyno-Yasenetsky State Medical University, st. Partizana Zheleznyaka 1, Krasnoyarsk, 660022 Russia
    2University of Ottawa, 10 Marie-Curie, Ottawa, K1N 6N5, Canada

    ---------------------------------------------------------------------------------------------------------------

    Identification of protein targets for the aptamers with antitumor activity against ahrlich ascites adenocarcinoma cells

    T.N. Zamay1, O.S. Kolovskaya1, Y.E. Glazyrin1, E.A. Spivak1, O.A. Zubkova1, G.S. Zamay1, M.V. Berezovsky2, A.S. Zamay1

    1Krasnoyarsk State Medical University, P. Zheleznyaka 1, Krasnoyarsk, 660022 Russia
    2University of Ottawa, 10 Marie-Curie, Ottawa, K1N 6N5, Canada

    ---------------------------------------------------------------------------------------------------------------

  • Gold Sponsor and Exhibitor

    Aptamer Group UK

    Aptamer Solutions Ltd is a York based Biotechnology Company specialising in the custom selection of high-affinity and highly specific nucleic acid aptamers for use in the life sciences sector. Our proprietary automated high-throughput aptamer selection processes allow us to offer a flexible and competitive pricing structure for the development of RNA and DNA aptamers. In addition, we are about to launch a new complementary technology in the area of biomarker discovery.

    Our proprietary aptamer based biomarker discovery platform and proprietary combinatorial libraries contain up to and over 1018 different molecules, this diversity and bespoke library design is fundamental to the success of the screening process. This technology enables us to greatly speed up the identification of novel biomarkers as well as diagnostics and/or therapeutic candidate molecules. This technology builds on one of the most powerful uses of aptamer technology, which is the ability for aptamers to be isolated against targets without any prior knowledge of the target.

    Our aptamer-based proteomic technology identifies novel biomarkers within the cell surface (such as tumours, cell lines or stem cells) or in samples of biological fluids (such as, urine, plasma and saliva). The technology is versatile and can also be applied to viruses, bacteria, fungi or any other cell based materials or extracts. The discovery process is driven by identifying differences between sample population using enormous aptamer libraries. Samples are prepared based on broad classifications such as: disease vs normal; pre-metastatic vs. post metastatic cancers; pathogenic vs non-pathogenic fungi etc. The process is fast and efficient and identifies differences between ‘healthy’ and ‘diseased’ whilst simultaneously developing the affinity reagent. This cuts out many of the steps associated with traditional biomarker discovery processes.

    Exhibitor
    IDTDNA

    Integrated DNA Technologies (IDT) is a leader in the manufacture and development of products for the research and diagnostic life science market. T he largest supplier of custom nucleic acids in the world, IDT serves academic research, biotechnology, and pharmaceutical development communities.

    IDT products support a wide variety of applications, including next generation sequencing (NGS), DNA amplification, SNP detection, microarray analysis, expression profiling, gene quantification, and synthetic biology. Platform-independent NGS products and services are available in addition to DNA and RNA oligonucleotides, qPCR assays, siRNA duplexes, and custom gene synthesis. Individually-synthesized xGen™ Lockdown™ Probes enable improved target capture. IDT also manufactures custom adaptors, fusion primers, Molecular Identifier tags (MIDs), and other workflow oligonucleotides for NGS. A TruGrade™ processing service is also available to reduce oligonucleotide crosstalk during multiplex NGS.

    Serving over 80,000 life sciences researchers, IDT is widely recognized as the industry leader in custom oligonucleotide manufacture due to its unique capabilities. IDT pioneered the use of high throughput quality control (QC) methods and is the only oligonucleotide manufacturer to offer purity guarantees and 100% QC. Every oligonucleotide is analyzed by mass spectrometry and purified oligonucleotides receive further analysis by CE and HPLC. The company maintains an engineering division dedicated to advancing synthesis, processing technology, and automation. An in-house machine shop provides rapid prototyping and custom part design/control. Additionally, IDT offers unrivalled customer support, receiving approximately 100,000 calls annually with an average wait time of only 8 seconds.

    A dedicated GMP manufacturing facility for molecular diagnostics provides oligonucleotides for In Vitro Diagnostic Devices (IVDs) or Analyte Specific Reagents (ASRs) for Laboratory-Developed Tests (LDTs). This manufacturing process is customer-defined and controlled, and facilitates progression from research to commercialization.

    Exhibitor
    IZON

    OVERVIEW: Izon designs and manufactures precision instrumentation for multi-parameter measurement of nano- and micro- sized particles. Izon’s instruments use unique nanopore-based detection to enable the size, charge and concentration of 50nm -  20 micron sized particles to be measured on a particle-by-particle basis, providing detail not available with optical-based techniques. Izon originated in New Zealand and now sells its products in 34 countries. It has its European headquarters in Oxford, UK and its US headquarters are in Cambridge, MA.

    APPLICATIONS: The underlying measurement technique known as Tunable Resistive Pulse Sensing (TRPS) has been applied to enable high resolution analysis of a wide range of particle types in fields including:

    >Drug Delivery Research: e.g. Liposomes, Nanobubbles, Polymeric Drug Delivery
    >Virus Quantification: e.g. Viral Vaccines, Adenovirus, Lentivirus
    >Microvesicle Research & Haematology: e.g. Microparticles & Exosomes, While Blood Cells, Platelets

    PRODUCTS: Two instruments based on TRPS technology are currently commercially available:

    >qNano is a compact benchtop device for highly precise physical characterization (size, zeta-potential, concentration) of a wide range of particle types
    >qViro-X is a purpose-built virus analysis instrument ideal for assessment of viral titre and aggregation. It meets stringent decontamination requirements ideal for manufacturing and quality control environments.

    Biomedical Diagnostics Projects: High-resolution detection of particle size and charge, enables assays to be developed for high sensitivity detection of target analytes. Projects are underway to combine magnetic particle sensing systems with TRPS to provide high-sensitivity diagnostics for clinical use that are faster and lower cost than existing methods.

    Website: http://www.izon.com

    FOLLOW US:

    Facebook: http://www.facebook.com/izonscience
    Twitter: http://www.twitter.com/izonscience
    For further information please email info@izon.com

    Exhibitor
    iba

    IBA GmbH – Your partner for custom-made Aptamers

    IBA GmbH is a biotech company located in Goettingen, Germany. Since 1991 our nucleic acid division has focused on specialized nucleic acid custom services, which require particular care and highest quality. These include custom-made DNA and RNA oligonucleotides, chimers, modified and labeled nucleic acids (e.g. for real-time PCR) as well as dinucleotides and triphosphates.

    Taking advantage of the new Click Chemistry we can offer new dye combination options and unsurpassed labeling densities. More than 200 fluorescent labels and more than 80 modifications are available to suit your needs.

    With our expertise in high quality oligonucleotide synthesis we produce custom DNA and RNA Aptamers according to your individual specifications. You ask for it - we synthesize! Just let us know your DNA/RNA sequence and required modification.

    In collaboration with RiNA GmbH, Berlin, we are now also providing an Aptamer Generation Service (AGS), which enables the generation of new DNA or RNA Aptamers.

    More details can be found at www.oligo-specialist.com.

    Exhibitor
    RiNA

    RiNA GmbH, a biotech company located in Berlin (Germany), is active in the field of cell-free protein biosynthesis and functional nucleic acids, especially in aptamer technology and its application. RiNA provides both commercial protein expression kits and diverse services for protein and nucleic acids syntheses.

    RiNA’s Functional Nucleic Acids (FuNA) division provides different services in the aptamer field, in particular:

    • Development of new aptamer against all kinds of targets, such as organic molecules, proteins or cells, is supplied by an Aptamer Generation Service (AGS). The AGS consists of four project phases (in vitro selection, sequence analysis, characterization and delivery of aptamers) with milestone depending payments. RiNA’s automatic in vitro selection process enables the aptamer development against different targets in parallel.
    • Synthesis of already existing aptamers is supplied by an Aptamer Synthesis Service (ASS) in cooperation with our partner IBA GmbH (Germany). The ASS enables the purchase of a broad range published and inhouse developed aptamers (DNA, RNA and also peptides aptamers) complied in RiNA’s Aptamer Catalog.
    • Development of new aptamer applications includes solutions in diagnostic and environmental analysis, for instance the development of aptamer-based biosensors (aptasensors).

     

    Additionally, RiNA is currently involved in several national and international funded projects.

    For further information please send an email to info@rina-gmbh.eu or visit our website (www.rina-gmbh.eu).

    Exhibitor

    BasePairBiotech

    Base Pair Biotechnologies offers its customers a total solution for developing novel DNA and RNA aptamer-based technologies.  In addition to our numerous institutional customers, we support companies developing products in areas ranging from basic research detection, to clinical diagnostics and therapeutic lead development.  We have proven success with protein, peptide, small molecule and cellular targets.

    Our platform technology is a patented, multiplexed approach to aptamer discovery.  This allows us to offer de novo aptamer discovery services at unprecedented speed and throughput.  Our expertise in aptamer and related assay development allows us to support our customers in a wide range of novel applications.

    Scientists at Base Pair Biotechnologies have been studying aptamers and developing them on a research basis since 2004.  Besides custom aptamer development through commercial and research requests Base Pair Biotechnologies is also involved in multiple projects funded through research grants.  Current and past federally funded research projects involving aptamers include NIH, EPA and NSF grants totaling over $2.5M.

    Besides our custom work we have hundreds of aptamers with validated binding on hand with various degrees of prior validation in assays as well. Our Aptamers that Work™ catalog and catalog incubator contain DNA and RNA aptamers available for use.

  • The following organisations were represented at the symposium.

    • 2Bind GmbH, Germany
    • A4 Lifesciences, The Netherlands
    • AptaIT GmbH, Germany
    • Aptamer Group, UK
    • AstraZeneca, UK
    • Base Pair Biotechnologies Inc, USA
    • BBI Group, UK
    • bioMérieux sa, France
    • CEA, Institut d’imagerie biomédicale, S INSERM, France
    • CNRS/INSERM, France
    • Deakin University, Australia
    • Frankfurt University, Germany
    • Gottfried-Wilhelm-Leibniz University, Germany
    • Helmholtz Centre for Environmental Research GmbH – UFZ, Germany
    • Horiba Scientific, France
    • iba GmbH, Germany
    • Institut Européen de Chimie et Biologie, France
    • Institut für Technische Chemie, Hannover, Germany
    • Institut Nanoscience et Cryogénie, France
    • Institute of Chemical Biology and Fundamental Medicine, Russian Federation
    • Institute of Experimental Endocrinology and Oncology ”G. Salvatore”  Italy
    • Integrated DNA Technologies, UK
    • Integrated DNA Technologies, USA
    • Istituto Italiano di Tecnologia, Italy
    • IZON Science, New Zealand
    • Krasnoyarsk State Med University, Russian Federation
    • Kyowa Hakko Kirin California Inc, USA
    • Leeds University, UK
    • Liverpool University, UK
    • Loughborough University, UK
    • Merck Millipore, Ireland
    • National University of Ireland Galway, Ireland
    • NOXXON Pharma AG, Germany
    • RiNA GmbH, Germany
    • SomaLogic Inc, USA
    • Technical University Darmstadt, Germany
    • Technion Haifa, Israel
    • The University of Texas, USA
    • UMR CNRS, France
    • Universitat Rovira i Virgili, Spain
    • University Hospital Tuebingen, Germany
    • University of Antwerp, Belgium
    • University of Bonn, Germany
    • University of Central Lancashire, UK
    • University of Grenoble, France
    • University of Hamburg, Germany
    • University of Jordan, Jordan
    • University of Paris, France
    • University of Salford, UK
    • University of Southern Denmark, Denmark
    • University of Toronto, Canada

    video

    • https://www.youtube.com/watch?v=n9EUqIoBJXA